Completed NA INTERVENTIONAL 2-arm NCT03591224

Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy

A Randomized Controlled Trial of Pharmacogenomic Guided Versus Standard Pharmacist Care to Optimize Antidepressant Drug Therapy in a Community Pharmacy Setting

Sponsor: Green Shield Canada

Conditions Anxiety Depression Generalized Anxiety Disorder Major Depressive Disorder Mood Disorders

Interventions Pharmacist Standard of Care Pharmacogenomic Testing

Updated 5 times since 2018 Last updated: Jul 1, 2020 Started: Apr 17, 2018 Primary completion: Dec 31, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03591224, this NA trial focuses on Anxiety and Depression and remains completed. Sponsored by Green Shield Canada, it has been updated 5 times since 2018, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Aug 2020 — Jan 2021 [monthly]

Completed NA

Status: Recruiting → Completed
Aug 2018 — Aug 2020 [monthly]

Recruiting NA

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Green Shield Canada
John Papastergiou Pharmacy Ltd

Data source: John Papastergiou Pharmacy Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada